X0508 4 2026-02-02 0001062822 LEXICON PHARMACEUTICALS, INC. LXRX 0002005369 Invus Global Management, LLC 750 LEXINGTON AVENUE, 30TH FLOOR NEW YORK NY 10022 true false true false 0002005245 Siren, L.L.C. C/O THE INVUS GROUP, LLC 750 LEXINGTON AVENUE 30TH FLOOR NEW YORK NY 10022 true false true false 0001053890 DEBBANE RAYMOND C/O THE INVUS GROUP, LLC 750 LEXINGTON AVENUE 30TH FLOOR NEW YORK NY 10022 true false false false 0002048403 Artal Participations S.a r.l. VALLEY PARK 44, RUE DE LA VALLEE LUXEMBOURG N4 L-2661 LUXEMBOURG true false true false 0001218180 Artal International S.C.A. VALLEY PARK, 44, RUE DE LA VALLEE LUXEMBOURG N4 L-2661 LUXEMBOURG true false true false 0001522131 Artal International Management S.A. VALLEY PARK, 44, RUE DE LA VALLEE LUXEMBOURG N4 L-2661 LUXEMBOURG true false true false 0001053906 Artal Group S.A. VALLEY PARK, 44, RUE DE LA VALLEE LUXEMBOURG N4 L-2661 LUXEMBOURG true false true false 0001283968 Westend S.A. VALLEY PARK, 44, RUE DE LA VALLEE LUXEMBOURG N4 L-2661 LUXEMBOURG true false true false 0001460840 Stichting Administratiekantoor Westend H.J.E. WENCKEBACHWEG 252 AMSTERDAM P7 1096 AS NETHERLANDS true false true false false Common Stock 2026-02-02 4 A false 18553846 1.30 A 154734327 I See Footnotes Common Stock 2026-02-02 4 A false 3846154 1.30 A 7362368 I See Footnotes Common Stock 2026-02-02 4 P false 1538462 1.30 A 1538462 I See Footnotes Series B Convertible Preferred Stock 2026-02-02 4 A false 367145.12 65.00 A 367145.12 I See Footnotes Common Stock 35402689 I See Footnotes Common Stock 5451204 I See Footnotes Common Stock 1385689 I See Footnotes On January 29, 2026, Artal Participations S.a r.l. entered into a purchase agreement with the Issuer pursuant to which Artal Participations S.a r.l. agreed to purchase 22,400,000 shares of common stock par value $0.001 per share (the "Common Stock") of the Issuer at a price of $1.30 per share (the "Purchase Price"). On January 30, 2026, Artal Participations S.a r.l. assigned its right to purchase from the Issuer 3,846,154 shares of Issuer Common Stock to Invus Public Equities, L.P., and Invus Public Equities, L.P. agreed to purchase directly from the Issuer 3,846,154 shares of Issuer Common Stock at the Purchase Price. The purchase closed on February 2, 2026. On February 2, 2026, Avicenna Life Sci Master Fund LP purchased 1,538,462 shares of Common Stock as part of the Issuer's underwritten public offering. On January 29, 2026, Artal Participations S.a r.l. entered into a preferred stock purchase agreement (the "Preferred Purchase Agreement") with the Issuer pursuant to which Artal Participations S.a r.l. agreed to purchase 367,145.12 shares of Series B Convertible Preferred Stock, par value $0.01 per share (the "Preferred Stock") of the Issuer at a price of $65.00 per share. The Preferred Purchase Agreement also provides Artal Participations S.a r.l. the right to purchase from the Issuer, up to an additional 94,854.88 shares of Preferred Stock at a price per share of $65.00. Each share of Preferred Stock will automatically convert into 50 shares of the Issuer's Common Stock upon receipt of shareholder approval and the satisfaction of certain other conditions; however, absent the satisfaction of such conditions, the shares are not convertible. The purchase closed on February 2, 2026. These securities are directly held by Artal Participations S.a r.l. These securities are directly held by Invus Public Equities, L.P. These securities are directly held by Avicenna Life Sci Master Fund LP These securities are directly held by Invus, L.P. These securities are directly held by Invus US Partners LLC The sole shareholder of Artal Participations S.a r.l. is Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. The managing member of Invus Public Equities Advisors, LLC is Invus Global Management, LLC. The managing member of Invus Global Management, LLC is Siren, L.L.C. The managing member of Siren, L.L.C. is Mr. Raymond Debbane. The general partner of Avicenna Life Sci Master Fund LP is Avicenna Life Sci Master GP LLC. The managing member of Avicenna Life Sci Master GP LLC is Ulys, L.L.C. The managing member of Ulys, L.L.C. is Mr. Raymond Debbane. The general partner of Invus, L.P. is Invus Advisors, L.L.C. The managing member of Invus Advisors, L.L.C. is Invus Global Management, LLC. The managing member of Invus Global Management, LLC. is Siren, L.L.C. The managing member of Siren, L.L.C. is Mr. Raymond Debbane. The managing member of Invus US Partners LLC is Ulys, L.L.C. The managing member of Ulys, L.L.C. is Mr. Raymond Debbane. These securities are directly held by Mr. Raymond Debbane. Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. For purposes of Section 16 of the Exchange Act, the Reporting Persons may be deemed to be directors by deputization of the Issuer by virtue of Invus, L.P.'s right to designate certain members of the Issuer's board of directors pursuant to a stockholders' agreement between the Issuer and Invus, L.P. See Exhibit 99.1 2026-02-04